A new peer-reviewed case series suggests that semaglutide — the active ingredient in Ozempic and Wegovy — may help treat chronic, hard-to-manage diarrhea across a range of underlying causes. The finding is a potential bright spot for the millions of people whose daily lives are disrupted by unpredictable bowel movements and fecal incontinence.
What the Study Found
Researchers published their findings in the Scandinavian Journal of Gastroenterology, reporting on compassionate use of weekly semaglutide in 30 patients with intractable diarrhea of different etiologies — meaning diarrhea that had been difficult or impossible to control and stemmed from multiple different underlying causes. The authors noted that while a related GLP-1 drug, liraglutide, has previously been documented as effective specifically in patients with bile acid diarrhea (BAD), evidence for semaglutide's effect on broader, less specified forms of chronic diarrhea had been lacking before this publication.
Why This Matters for GLP-1 Users
For people already taking semaglutide for diabetes management or weight loss, this research adds important nuance. GLP-1 medications are commonly associated with gastrointestinal side effects — including diarrhea — particularly during dose escalation. The idea that the same drug class might treat certain forms of chronic diarrhea in other patients underscores how complex GLP-1's effects on the gut really are. It also opens a potential new therapeutic use for patients who are currently suffering with conditions that have few good treatment options.
- The study specifically involved patients with intractable diarrhea — cases that had not responded well to standard treatments
- Multiple underlying causes of diarrhea were represented in the 30-patient cohort
- Treatment was administered under compassionate use, meaning it was provided outside of standard regulatory approval for this indication
Key takeaway: Semaglutide is not currently approved to treat chronic diarrhea — this was compassionate use in a small case series of 30 patients. Speak with your doctor before drawing any conclusions about your own GI symptoms.
Important Limitations to Keep in Mind
As promising as these early findings are, it is important to put them in context. A case series of 30 patients is a relatively small, preliminary form of evidence. Case series do not include a control group, which makes it harder to rule out placebo effects or natural disease fluctuation. Larger, controlled clinical trials would be needed before semaglutide could be recommended — or approved — specifically for chronic diarrhea. Patients should not adjust their medication use based on this early research alone.
What to Watch Next
This publication may prompt interest in more rigorous clinical trials exploring GLP-1 receptor agonists as a treatment for chronic gastrointestinal conditions beyond diabetes and obesity. Researchers and gastroenterologists will likely be watching closely to see whether these results can be replicated in larger, randomized studies. Given the significant unmet need for patients with intractable diarrhea, the field could move relatively quickly if early signals continue to look positive.
Frequently Asked Questions
If you are experiencing chronic diarrhea or any persistent gastrointestinal symptoms — whether or not you are currently taking a GLP-1 medication — speak with your prescriber or a gastroenterologist for personalized guidance. Do not start, stop, or change any medication based on preliminary research alone.
- Peer-reviewed journal article, 'Semaglutide for treatment of intractable diarrhea of different etiologies: a case series of 30 patients,' Scandinavian Journal of Gastroenterology, date not specified in source.